Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.

Journal of hepatology - 1 Oct 2010

Cheng Wendy S C, Roberts Stuart K, McCaughan Geoffrey, Sievert William, Weltman Martin, Crawford Darrell, Rawlinson William, Marks Philippa S, Thommes James, Rizkalla Bishoy, Yoshihara Motoko, Dore Gregory J

Abstract excerpt

BACKGROUND & AIMS: The impact of fibrosis stage on chronic hepatitis C virus (HCV) treatment response was explored in CHARIOT, a study of high dose peginterferon alfa-2a (PEG-IFNalpha-2a) induction therapy in treatment naïve genotype 1 infection. METHODS: Eight hundred and ninety-six patients wer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepatitis C

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 20619475
DOI: 10.1016/j.jhep.2010.04.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20619475-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.PMID 20619475Read ↗

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.Semantic proximity Read ↗

Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients.Semantic proximity Read ↗

Hepatitis C treatment response kinetics and impact of baseline predictors.Semantic proximity Read ↗

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).Semantic proximity Read ↗

Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.Semantic proximity Read ↗

A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis c: pretreatment stratification by viral burden and genotype.Semantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.Semantic proximity Read ↗

Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.Semantic proximity Read ↗

Prediction of virologic response in difficult-to-treat chronic hepatitis C patients during high-dose interferon induction therapy.Semantic proximity Read ↗

High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.Semantic proximity Read ↗

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.Semantic proximity Read ↗

Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.